Founded in 1989 and with headquarters in Ann Arbor, Michigan, Aastrom Biosciences is dedicated to the development of stem cell treatments for critical cardiovascular diseases. Aastrom is currently evaluating its autologous cellular therapies in late-stage U.S. clinical trials in the treatment of critical limb ischemia (CLI) and dilated cardiomyopathy (DCM). These critical diseases are associated with significant morbidity and mortality and very limited treatment options.
Market Capitalization: $77.5M
Current Revenue: Minimal
Cash Burn: In excess of $20M including clinical trials
Cash and Liquid Investments to Current Liabilities: $29M/$12M
Clinical Status: In Phase III for CLI; Phase II for Dilated cardiomyopathy